SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2qyk'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EI6_D_PPFD412_1 (PHOSPHONOACETATE HYDROLASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 8	THR A 483 ASP A 413 HIS A 372 HIS A 376	MG A 2 ( 4.9A) MG A 2 ( 2.6A) NPV A 3 (-4.6A) ZN A 1 (-3.3A)	1.03A	1ei6D-2qykA: undetectable	1ei6D-2qykA: 23.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FM6_U_9CRU502_1 (RETINOIC ACID RECEPTOR RXR-ALPHA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	ALA A 409 ALA A 408 LEU A 381 ILE A 349 LEU A 472	None	1.00A	1fm6U-2qykA: undetectable	1fm6U-2qykA: 23.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1GSE_A_EAAA224_1 (GLUTATHIONE TRANSFERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	ARG A 341 LEU A 403 LEU A 472 VAL A 476 ALA A 410	None	1.09A	1gseA-2qykA: undetectable	1gseA-2qykA: 21.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	6 / 10	TYR A 371 HIS A 372 PHE A 552 GLN A 581 GLY A 583 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) None NPV A 3 (-3.3A)	0.40A	1uhoA-2qykA: 36.3	1uhoA-2qykA: 29.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1WRL_A_TFPA204_1 (TROPONIN C, SLOW SKELETAL AND CARDIAC MUSCLES)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 7	LEU A 464 PHE A 338 MET A 354 VAL A 355	None	1.05A	1wrlA-2qykA: undetectable 1wrlB-2qykA: undetectable	1wrlA-2qykA: 15.19 1wrlB-2qykA: 15.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	HIS A 412 MET A 485 THR A 545 GLN A 581 PHE A 584	ZN A 1 (-3.3A) None NPV A 3 ( 4.7A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	1.44A	1xlxA-2qykA: 52.3	1xlxA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 HIS A 416 MET A 485 LEU A 531 ASN A 533 THR A 545 ILE A 548 MET A 549 SER A 580 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None None NPV A 3 (-4.4A) NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.37A	1xlxA-2qykA: 52.3	1xlxA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	HIS A 412 MET A 485 THR A 545 GLN A 581 PHE A 584	ZN A 1 (-3.3A) None NPV A 3 ( 4.7A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	1.45A	1xlxB-2qykA: 52.4	1xlxB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 HIS A 416 MET A 485 THR A 545 ILE A 548 MET A 549 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.38A	1xlxB-2qykA: 52.4	1xlxB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 HIS A 416 MET A 485 THR A 545 ILE A 548 MET A 549 PHE A 552 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.54A	1xlxB-2qykA: 52.4	1xlxB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 ASP A 530 LEU A 531 PRO A 534 TYR A 541 TRP A 544 ILE A 548 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) ZN A 1 (-2.5A) None None None None NPV A 3 (-3.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.49A	1xmuA-2qykA: 52.9	1xmuA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 ASP A 530 LEU A 531 PRO A 534 TYR A 541 TRP A 544 ILE A 548 PHE A 552 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) ZN A 1 (-2.5A) None None None None NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.38A	1xmuA-2qykA: 52.9	1xmuA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 5	MET A 485 ASN A 533 THR A 545 MET A 549 GLN A 581	None NPV A 3 (-4.4A) NPV A 3 ( 4.7A) NPV A 3 ( 4.7A) NPV A 3 (-3.1A)	0.21A	1xmuA-2qykA: 52.9	1xmuA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 PRO A 534 TYR A 541 TRP A 544 ILE A 548 PHE A 552 MET A 569 SER A 580	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None None None None NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A)	0.45A	1xmuB-2qykA: 52.4	1xmuB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 5	ASN A 533 THR A 545 MET A 549 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 ( 4.7A) NPV A 3 ( 4.7A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.26A	1xmuB-2qykA: 52.4	1xmuB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	6 / 12	TYR A 371 ASP A 413 ILE A 548 MET A 549 PHE A 552 MET A 569	NPV A 3 (-4.4A) MG A 2 ( 2.6A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A)	1.45A	1xomA-2qykA: 52.4	1xomA-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 ILE A 548 MET A 549 PHE A 552 MET A 569 SER A 580 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.42A	1xomA-2qykA: 52.4	1xomA-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 LEU A 531 THR A 545 ILE A 548 MET A 549 PHE A 552 MET A 569 SER A 580 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.43A	1xomB-2qykA: 52.0	1xomB-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	7 / 12	TYR A 371 HIS A 376 MET A 485 THR A 545 SER A 580 GLN A 581 PHE A 584	NPV A 3 (-4.4A) ZN A 1 (-3.3A) None NPV A 3 ( 4.7A) NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	1.48A	1xomB-2qykA: 52.0	1xomB-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 PRO A 534 TYR A 541 THR A 545 ILE A 548 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.52A	1xoqA-2qykA: 52.5	1xoqA-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	ASN A 533 TRP A 544 GLN A 581	NPV A 3 (-4.4A) None NPV A 3 (-3.1A)	0.13A	1xoqA-2qykA: 52.5	1xoqA-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 ASP A 530 LEU A 531 PRO A 534 TYR A 541 TRP A 544 THR A 545 ILE A 548 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) ZN A 1 (-2.5A) None None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.49A	1xoqB-2qykA: 51.9	1xoqB-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	MET A 485 ASN A 533 GLN A 581	None NPV A 3 (-4.4A) NPV A 3 (-3.1A)	0.32A	1xoqB-2qykA: 51.9	1xoqB-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 MET A 549 PHE A 552 MET A 569 GLN A 581 PHE A 584 ILE A 588	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None NPV A 3 ( 4.7A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A) None	0.42A	1xosA-2qykA: 52.1	1xosA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	7 / 12	TYR A 371 HIS A 376 MET A 485 LEU A 531 GLN A 581 PHE A 584 ILE A 588	NPV A 3 (-4.4A) ZN A 1 (-3.3A) None None NPV A 3 (-3.1A) NPV A 3 (-3.3A) None	1.49A	1xosA-2qykA: 52.1	1xosA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	8 / 12	TYR A 371 MET A 485 ASP A 530 LEU A 531 MET A 549 PHE A 552 SER A 567 PHE A 584	NPV A 3 (-4.4A) None ZN A 1 (-2.5A) None NPV A 3 ( 4.7A) NPV A 3 (-4.8A) None NPV A 3 (-3.3A)	1.15A	1xosA-2qykA: 52.1	1xosA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 LEU A 531 ILE A 548 MET A 549 SER A 567 MET A 569 SER A 580 GLN A 581 PHE A 584 ILE A 588	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 (-3.8A) NPV A 3 ( 4.7A) None NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A) None	0.77A	1xotA-2qykA: 52.3	1xotA-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 MET A 485 LEU A 531 ASN A 533 ILE A 548 MET A 549 SER A 567 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 (-4.4A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) None NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.63A	1xotB-2qykA: 52.3	1xotB-2qykA: 87.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	11 / 12	TYR A 371 HIS A 372 MET A 485 LEU A 531 ASN A 533 ILE A 548 MET A 549 SER A 567 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None None NPV A 3 (-4.4A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) None NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.69A	1xotB-2qykA: 52.3	1xotB-2qykA: 87.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	TYR A 371 HIS A 372 PHE A 552 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.44A	2h42A-2qykA: 36.1	2h42A-2qykA: 29.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	TYR A 371 LEU A 531 PHE A 552 GLN A 581 PHE A 584	NPV A 3 (-4.4A) None NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.42A	2h42C-2qykA: 35.9	2h42C-2qykA: 29.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q0J_B_BEZB500_0 (QUINOLONE SIGNAL RESPONSE PROTEIN)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	ASP A 413 HIS A 412 ASP A 530 LEU A 531 HIS A 376	MG A 2 ( 2.6A) ZN A 1 (-3.3A) ZN A 1 (-2.5A) None ZN A 1 (-3.3A)	1.25A	2q0jB-2qykA: undetectable	2q0jB-2qykA: 22.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	9 / 12	TYR A 371 HIS A 372 LEU A 531 ILE A 548 GLU A 551 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None NPV A 3 (-3.8A) None NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	1.00A	2weyA-2qykA: 38.0	2weyA-2qykA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 8	ILE A 548 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.87A	2weyB-2qykA: 37.7	2weyB-2qykA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ARR_A_PNXA607_1 (CHITINASE A)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 7	VAL A 380 SER A 532 THR A 384 LEU A 387	None	1.21A	3arrA-2qykA: undetectable	3arrA-2qykA: 18.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	6 / 12	TYR A 371 HIS A 372 LEU A 531 PHE A 552 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.61A	3b2rA-2qykA: 31.5	3b2rA-2qykA: 29.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	TYR A 371 HIS A 372 LEU A 531 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.49A	3b2rB-2qykA: 31.5	3b2rB-2qykA: 29.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CZV_A_AZMA263_1 (CARBONIC ANHYDRASE 13)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	HIS A 376 HIS A 412 PHE A 584 THR A 483 VAL A 589	ZN A 1 (-3.3A) ZN A 1 (-3.3A) NPV A 3 (-3.3A) MG A 2 ( 4.9A) None	1.13A	3czvA-2qykA: undetectable 3czvB-2qykA: undetectable	3czvA-2qykA: 20.62 3czvB-2qykA: 20.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASN A 533 PRO A 534 TYR A 541 TRP A 544 THR A 545 ILE A 548 MET A 569 SER A 580 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None NPV A 3 (-4.4A) None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 (-3.1A) NPV A 3 (-4.5A) NPV A 3 (-3.3A)	0.49A	3g4lA-2qykA: 51.8	3g4lA-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	ASP A 530 LEU A 531 GLN A 581	ZN A 1 (-2.5A) None NPV A 3 (-3.1A)	0.35A	3g4lA-2qykA: 51.8	3g4lA-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 PRO A 534 TRP A 544 THR A 545 ILE A 548 MET A 549 MET A 569 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.41A	3g4lB-2qykA: 52.0	3g4lB-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 ASN A 533 PRO A 534 TYR A 541 TRP A 544 THR A 545 ILE A 548 MET A 569	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None NPV A 3 (-4.4A) None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 (-3.1A)	0.42A	3g4lC-2qykA: 52.2	3g4lC-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	SER A 580 GLN A 581 PHE A 584	NPV A 3 (-4.5A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.22A	3g4lC-2qykA: 52.2	3g4lC-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	12 / 12	TYR A 371 HIS A 372 MET A 485 ASP A 530 LEU A 531 PRO A 534 TRP A 544 THR A 545 ILE A 548 MET A 549 SER A 580 GLN A 581	NPV A 3 (-4.4A) NPV A 3 (-4.6A) None ZN A 1 (-2.5A) None None None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 ( 4.7A) NPV A 3 (-4.5A) NPV A 3 (-3.1A)	0.33A	3g4lD-2qykA: 53.9	3g4lD-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	7 / 12	TYR A 371 HIS A 376 MET A 485 LEU A 531 THR A 545 SER A 580 GLN A 581	NPV A 3 (-4.4A) ZN A 1 (-3.3A) None None NPV A 3 ( 4.7A) NPV A 3 (-4.5A) NPV A 3 (-3.1A)	1.49A	3g4lD-2qykA: 53.9	3g4lD-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	ASN A 533 MET A 569 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.69A	3g4lD-2qykA: 53.9	3g4lD-2qykA: 85.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	8 / 9	TYR A 371 ASN A 533 ILE A 548 PHE A 552 MET A 569 GLN A 581 PHE A 584 ILE A 588	NPV A 3 (-4.4A) NPV A 3 (-4.4A) NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A) None	0.34A	3iakA-2qykA: 51.7	3iakA-2qykA: 82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	8 / 9	TYR A 371 MET A 485 ASN A 533 ILE A 548 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) None NPV A 3 (-4.4A) NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.59A	3iakA-2qykA: 51.7	3iakA-2qykA: 82.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ID5_B_SAMB301_0 (FIBRILLARIN-LIKE RRNA/TRNA 2'-O-METHYLTRANSFERA SE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	THR A 298 ASP A 379 ALA A 378 ILE A 333 GLN A 382	None	0.99A	3id5B-2qykA: undetectable	3id5B-2qykA: 21.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ID5_F_SAMF301_0 (FIBRILLARIN-LIKE RRNA/TRNA 2'-O-METHYLTRANSFERA SE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	THR A 298 ASP A 379 ALA A 378 ILE A 333 GLN A 382	None	0.99A	3id5F-2qykA: undetectable	3id5F-2qykA: 21.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 9	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.90A	3jwqA-2qykA: 39.2	3jwqA-2qykA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.75A	3jwqB-2qykA: 39.1 3jwqC-2qykA: 39.2	3jwqB-2qykA: 29.07 3jwqC-2qykA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 7	TYR A 371 HIS A 372 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.81A	3jwqC-2qykA: 39.2	3jwqC-2qykA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	6 / 11	TYR A 371 HIS A 372 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.6A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.84A	3jwqA-2qykA: 39.2 3jwqD-2qykA: 38.8	3jwqA-2qykA: 29.07 3jwqD-2qykA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3R9V_B_DXCB1_0 (INVASIN IPAD)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 7	ILE A 519 LEU A 522 LEU A 393 VAL A 504	None	0.88A	3r9vA-2qykA: undetectable 3r9vB-2qykA: undetectable	3r9vA-2qykA: 21.02 3r9vB-2qykA: 21.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	9 / 9	TYR A 371 LEU A 531 ASN A 533 PRO A 534 THR A 545 ILE A 548 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) None NPV A 3 (-4.4A) None NPV A 3 ( 4.7A) NPV A 3 (-3.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.28A	3tvxA-2qykA: 56.1	3tvxA-2qykA: 98.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	7 / 7	TYR A 371 ASN A 533 ILE A 548 PHE A 552 MET A 569 GLN A 581 PHE A 584	NPV A 3 (-4.4A) NPV A 3 (-4.4A) NPV A 3 (-3.8A) NPV A 3 (-4.8A) NPV A 3 (-3.1A) NPV A 3 (-3.1A) NPV A 3 (-3.3A)	0.24A	3tvxB-2qykA: 56.1	3tvxB-2qykA: 98.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WFH_B_P2EB301_1 (MAB FAB H FRAGMENT MAB FAB L FRAGMENT)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	HIS A 445 VAL A 448 HIS A 416 PRO A 417 LEU A 431	None	1.32A	3wfhA-2qykA: undetectable 3wfhB-2qykA: undetectable	3wfhA-2qykA: 22.36 3wfhB-2qykA: 20.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WHX_B_XPGB301_1 (MAB FAB H FRAGMENT MAB FAB L FRAGMENT)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 12	HIS A 445 VAL A 448 HIS A 416 PRO A 417 LEU A 431	None	1.31A	3whxA-2qykA: undetectable 3whxB-2qykA: undetectable	3whxA-2qykA: 22.59 3whxB-2qykA: 20.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AX8_A_SAMA1474_1 (WBDD)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 6	TYR A 435 ASP A 415 GLU A 455 LEU A 446	None	1.21A	4ax8A-2qykA: undetectable	4ax8A-2qykA: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4FP9_A_SAMA401_1 (METHYLTRANSFERASE NSUN4)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	ASP A 616 ARG A 615 ASP A 609	None	0.85A	4fp9A-2qykA: undetectable	4fp9A-2qykA: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4JBT_B_ASDB502_1 (CYTOCHROME P450 MONOOXYGENASE)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 11	PHE A 338 ALA A 404 ALA A 405 THR A 384 VAL A 380	None	1.15A	4jbtB-2qykA: undetectable	4jbtB-2qykA: 23.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RKU_A_PQNA5001_1 (PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1 PHOTOSYSTEM I REACTION CENTER SUBUNIT IX)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 8	MET A 334 PHE A 338 ALA A 404 LEU A 403	None	0.99A	4rkuA-2qykA: undetectable 4rkuJ-2qykA: undetectable	4rkuA-2qykA: 17.63 4rkuJ-2qykA: 14.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XK8_A_PQNA844_1 (PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 7	MET A 334 PHE A 338 ALA A 404 LEU A 403	None	1.01A	4xk8A-2qykA: undetectable	4xk8A-2qykA: 17.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XK8_A_PQNA845_1 (PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 8	MET A 334 PHE A 338 ALA A 404 LEU A 403	None	1.00A	4xk8a-2qykA: undetectable	4xk8a-2qykA: 17.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XO7_A_ASDA402_1 (ALDO-KETO REDUCTASE FAMILY 1 MEMBER C2)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 7	VAL A 321 ILE A 318 LEU A 406 LEU A 381	None	0.81A	4xo7A-2qykA: undetectable	4xo7A-2qykA: 23.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_A_X6XA202_1 (GALNAC/GAL-SPECIFIC LECTIN)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 8	GLU A 551 VAL A 369 HIS A 372 ASP A 413 HIS A 445	None None NPV A 3 (-4.6A) MG A 2 ( 2.6A) None	1.16A	5f8yA-2qykA: undetectable	5f8yA-2qykA: 17.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F8Y_B_X6XB201_1 (GALNAC/GAL-SPECIFIC LECTIN)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	5 / 8	GLU A 551 VAL A 369 HIS A 372 ASP A 413 HIS A 445	None None NPV A 3 (-4.6A) MG A 2 ( 2.6A) None	1.18A	5f8yB-2qykA: undetectable	5f8yB-2qykA: 17.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5V4V_A_NCAA402_0 (NADPH DEHYDROGENASE 3)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 8	HIS A 527 PHE A 584 PRO A 534 TYR A 371	None NPV A 3 (-3.3A) None NPV A 3 (-4.4A)	1.28A	5v4vA-2qykA: undetectable	5v4vA-2qykA: 21.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5V4V_B_NCAB402_0 (NADPH DEHYDROGENASE 3)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	4 / 8	HIS A 527 PHE A 584 PRO A 534 TYR A 371	None NPV A 3 (-3.3A) None NPV A 3 (-4.4A)	1.29A	5v4vB-2qykA: undetectable	5v4vB-2qykA: 21.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	2qyk	CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10 (Homo sapiens)	3 / 3	TYR A 371 LEU A 375 ASP A 323	NPV A 3 (-4.4A) None None	0.87A	5zv2B-2qykA: undetectable	5zv2B-2qykA: 12.84

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1EI6_D_PPFD412_1","PHOSPHONOACETATE HYDROLASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"THR A 483;ASP A 413;HIS A 372;HIS A 376"," MG A   2 ( 4.9A); MG A   2 ( 2.6A);NPV A   3 (-4.6A); ZN A   1 (-3.3A)","1.03A","1ei6D-2qykA:undetectable","1ei6D-2qykA:23.76"],["1FM6_U_9CRU502_1","RETINOIC ACID RECEPTOR RXR-ALPHA","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"ALA A 409;ALA A 408;LEU A 381;ILE A 349;LEU A 472","None","1.00A","1fm6U-2qykA:undetectable","1fm6U-2qykA:23.44"],["1GSE_A_EAAA224_1","GLUTATHIONE TRANSFERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"ARG A 341;LEU A 403;LEU A 472;VAL A 476;ALA A 410","None","1.09A","1gseA-2qykA:undetectable","1gseA-2qykA:21.53"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",6,"TYR A 371;HIS A 372;PHE A 552;GLN A 581;GLY A 583;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);None;NPV A   3 (-3.3A)","0.40A","1uhoA-2qykA:36.3","1uhoA-2qykA:29.52"],["1WRL_A_TFPA204_1","TROPONIN C, SLOW SKELETAL AND CARDIAC MUSCLES;TROPONIN C, SLOW SKELETAL AND CARDIAC MUSCLES","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"LEU A 464;PHE A 338;MET A 354;VAL A 355","None","1.05A","1wrlA-2qykA:undetectable;1wrlB-2qykA:undetectable","1wrlA-2qykA:15.19;1wrlB-2qykA:15.19"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"HIS A 412;MET A 485;THR A 545;GLN A 581;PHE A 584"," ZN A   1 (-3.3A);None;NPV A   3 ( 4.7A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","1.44A","1xlxA-2qykA:52.3","1xlxA-2qykA:87.16"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;HIS A 416;MET A 485;LEU A 531;ASN A 533;THR A 545;ILE A 548;MET A 549;SER A 580;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;None;NPV A   3 (-4.4A);NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.37A","1xlxA-2qykA:52.3","1xlxA-2qykA:87.16"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"HIS A 412;MET A 485;THR A 545;GLN A 581;PHE A 584"," ZN A   1 (-3.3A);None;NPV A   3 ( 4.7A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","1.45A","1xlxB-2qykA:52.4","1xlxB-2qykA:87.16"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;HIS A 416;MET A 485;THR A 545;ILE A 548;MET A 549;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.38A","1xlxB-2qykA:52.4","1xlxB-2qykA:87.16"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;HIS A 416;MET A 485;THR A 545;ILE A 548;MET A 549;PHE A 552;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.54A","1xlxB-2qykA:52.4","1xlxB-2qykA:87.16"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;ASP A 530;LEU A 531;PRO A 534;TYR A 541;TRP A 544;ILE A 548;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A); ZN A   1 (-2.5A);None;None;None;None;NPV A   3 (-3.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.49A","1xmuA-2qykA:52.9","1xmuA-2qykA:87.16"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;ASP A 530;LEU A 531;PRO A 534;TYR A 541;TRP A 544;ILE A 548;PHE A 552;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A); ZN A   1 (-2.5A);None;None;None;None;NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.38A","1xmuA-2qykA:52.9","1xmuA-2qykA:87.16"],["1XMU_A_ROFA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"MET A 485;ASN A 533;THR A 545;MET A 549;GLN A 581","None;NPV A   3 (-4.4A);NPV A   3 ( 4.7A);NPV A   3 ( 4.7A);NPV A   3 (-3.1A)","0.21A","1xmuA-2qykA:52.9","1xmuA-2qykA:87.16"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;PRO A 534;TYR A 541;TRP A 544;ILE A 548;PHE A 552;MET A 569;SER A 580","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;None;None;None;NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A)","0.45A","1xmuB-2qykA:52.4","1xmuB-2qykA:87.16"],["1XMU_B_ROFB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"ASN A 533;THR A 545;MET A 549;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 ( 4.7A);NPV A   3 ( 4.7A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.26A","1xmuB-2qykA:52.4","1xmuB-2qykA:87.16"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",6,"TYR A 371;ASP A 413;ILE A 548;MET A 549;PHE A 552;MET A 569","NPV A   3 (-4.4A); MG A   2 ( 2.6A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A)","1.45A","1xomA-2qykA:52.4","1xomA-2qykA:82.16"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;ILE A 548;MET A 549;PHE A 552;MET A 569;SER A 580;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.42A","1xomA-2qykA:52.4","1xomA-2qykA:82.16"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;LEU A 531;THR A 545;ILE A 548;MET A 549;PHE A 552;MET A 569;SER A 580;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.43A","1xomB-2qykA:52.0","1xomB-2qykA:82.16"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",7,"TYR A 371;HIS A 376;MET A 485;THR A 545;SER A 580;GLN A 581;PHE A 584","NPV A   3 (-4.4A); ZN A   1 (-3.3A);None;NPV A   3 ( 4.7A);NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","1.48A","1xomB-2qykA:52.0","1xomB-2qykA:82.16"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;PRO A 534;TYR A 541;THR A 545;ILE A 548;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.52A","1xoqA-2qykA:52.5","1xoqA-2qykA:82.16"],["1XOQ_A_ROFA502_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"ASN A 533;TRP A 544;GLN A 581","NPV A   3 (-4.4A);None;NPV A   3 (-3.1A)","0.13A","1xoqA-2qykA:52.5","1xoqA-2qykA:82.16"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;ASP A 530;LEU A 531;PRO A 534;TYR A 541;TRP A 544;THR A 545;ILE A 548;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A); ZN A   1 (-2.5A);None;None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.49A","1xoqB-2qykA:51.9","1xoqB-2qykA:82.16"],["1XOQ_B_ROFB501_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"MET A 485;ASN A 533;GLN A 581","None;NPV A   3 (-4.4A);NPV A   3 (-3.1A)","0.32A","1xoqB-2qykA:51.9","1xoqB-2qykA:82.16"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;MET A 549;PHE A 552;MET A 569;GLN A 581;PHE A 584;ILE A 588","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;NPV A   3 ( 4.7A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A);None","0.42A","1xosA-2qykA:52.1","1xosA-2qykA:87.16"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",7,"TYR A 371;HIS A 376;MET A 485;LEU A 531;GLN A 581;PHE A 584;ILE A 588","NPV A   3 (-4.4A); ZN A   1 (-3.3A);None;None;NPV A   3 (-3.1A);NPV A   3 (-3.3A);None","1.49A","1xosA-2qykA:52.1","1xosA-2qykA:87.16"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",8,"TYR A 371;MET A 485;ASP A 530;LEU A 531;MET A 549;PHE A 552;SER A 567;PHE A 584","NPV A   3 (-4.4A);None; ZN A   1 (-2.5A);None;NPV A   3 ( 4.7A);NPV A   3 (-4.8A);None;NPV A   3 (-3.3A)","1.15A","1xosA-2qykA:52.1","1xosA-2qykA:87.16"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;LEU A 531;ILE A 548;MET A 549;SER A 567;MET A 569;SER A 580;GLN A 581;PHE A 584;ILE A 588","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 (-3.8A);NPV A   3 ( 4.7A);None;NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A);None","0.77A","1xotA-2qykA:52.3","1xotA-2qykA:87.16"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;MET A 485;LEU A 531;ASN A 533;ILE A 548;MET A 549;SER A 567;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 (-4.4A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);None;NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.63A","1xotB-2qykA:52.3","1xotB-2qykA:87.16"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",11,"TYR A 371;HIS A 372;MET A 485;LEU A 531;ASN A 533;ILE A 548;MET A 549;SER A 567;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;None;NPV A   3 (-4.4A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);None;NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.69A","1xotB-2qykA:52.3","1xotB-2qykA:87.16"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;HIS A 372;PHE A 552;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.44A","2h42A-2qykA:36.1","2h42A-2qykA:29.85"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;LEU A 531;PHE A 552;GLN A 581;PHE A 584","NPV A   3 (-4.4A);None;NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.42A","2h42C-2qykA:35.9","2h42C-2qykA:29.85"],["2Q0J_B_BEZB500_0","QUINOLONE SIGNAL RESPONSE PROTEIN","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"ASP A 413;HIS A 412;ASP A 530;LEU A 531;HIS A 376"," MG A   2 ( 2.6A); ZN A   1 (-3.3A); ZN A   1 (-2.5A);None; ZN A   1 (-3.3A)","1.25A","2q0jB-2qykA:undetectable","2q0jB-2qykA:22.93"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",9,"TYR A 371;HIS A 372;LEU A 531;ILE A 548;GLU A 551;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;NPV A   3 (-3.8A);None;NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","1.00A","2weyA-2qykA:38.0","2weyA-2qykA:29.18"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"ILE A 548;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.87A","2weyB-2qykA:37.7","2weyB-2qykA:29.18"],["3ARR_A_PNXA607_1","CHITINASE A","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"VAL A 380;SER A 532;THR A 384;LEU A 387","None","1.21A","3arrA-2qykA:undetectable","3arrA-2qykA:18.84"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",6,"TYR A 371;HIS A 372;LEU A 531;PHE A 552;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.61A","3b2rA-2qykA:31.5","3b2rA-2qykA:29.65"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;HIS A 372;LEU A 531;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.49A","3b2rB-2qykA:31.5","3b2rB-2qykA:29.65"],["3CZV_A_AZMA263_1","CARBONIC ANHYDRASE 13;CARBONIC ANHYDRASE 13","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"HIS A 376;HIS A 412;PHE A 584;THR A 483;VAL A 589"," ZN A   1 (-3.3A); ZN A   1 (-3.3A);NPV A   3 (-3.3A); MG A   2 ( 4.9A);None","1.13A","3czvA-2qykA:undetectable;3czvB-2qykA:undetectable","3czvA-2qykA:20.62;3czvB-2qykA:20.62"],["3G4L_A_ROFA901_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASN A 533;PRO A 534;TYR A 541;TRP A 544;THR A 545;ILE A 548;MET A 569;SER A 580;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None;NPV A   3 (-4.4A);None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 (-3.1A);NPV A   3 (-4.5A);NPV A   3 (-3.3A)","0.49A","3g4lA-2qykA:51.8","3g4lA-2qykA:85.63"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"ASP A 530;LEU A 531;GLN A 581"," ZN A   1 (-2.5A);None;NPV A   3 (-3.1A)","0.35A","3g4lA-2qykA:51.8","3g4lA-2qykA:85.63"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;PRO A 534;TRP A 544;THR A 545;ILE A 548;MET A 549;MET A 569;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.41A","3g4lB-2qykA:52.0","3g4lB-2qykA:85.63"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;ASN A 533;PRO A 534;TYR A 541;TRP A 544;THR A 545;ILE A 548;MET A 569","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;NPV A   3 (-4.4A);None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 (-3.1A)","0.42A","3g4lC-2qykA:52.2","3g4lC-2qykA:85.63"],["3G4L_C_ROFC903_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"SER A 580;GLN A 581;PHE A 584","NPV A   3 (-4.5A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.22A","3g4lC-2qykA:52.2","3g4lC-2qykA:85.63"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",12,"TYR A 371;HIS A 372;MET A 485;ASP A 530;LEU A 531;PRO A 534;TRP A 544;THR A 545;ILE A 548;MET A 549;SER A 580;GLN A 581","NPV A   3 (-4.4A);NPV A   3 (-4.6A);None; ZN A   1 (-2.5A);None;None;None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 ( 4.7A);NPV A   3 (-4.5A);NPV A   3 (-3.1A)","0.33A","3g4lD-2qykA:53.9","3g4lD-2qykA:85.63"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",7,"TYR A 371;HIS A 376;MET A 485;LEU A 531;THR A 545;SER A 580;GLN A 581","NPV A   3 (-4.4A); ZN A   1 (-3.3A);None;None;NPV A   3 ( 4.7A);NPV A   3 (-4.5A);NPV A   3 (-3.1A)","1.49A","3g4lD-2qykA:53.9","3g4lD-2qykA:85.63"],["3G4L_D_ROFD904_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"ASN A 533;MET A 569;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.69A","3g4lD-2qykA:53.9","3g4lD-2qykA:85.63"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",8,"TYR A 371;ASN A 533;ILE A 548;PHE A 552;MET A 569;GLN A 581;PHE A 584;ILE A 588","NPV A   3 (-4.4A);NPV A   3 (-4.4A);NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A);None","0.34A","3iakA-2qykA:51.7","3iakA-2qykA:82.16"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",8,"TYR A 371;MET A 485;ASN A 533;ILE A 548;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);None;NPV A   3 (-4.4A);NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.59A","3iakA-2qykA:51.7","3iakA-2qykA:82.16"],["3ID5_B_SAMB301_0","FIBRILLARIN-LIKE RRNA\/TRNA 2'-O-METHYLTRANSFERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"THR A 298;ASP A 379;ALA A 378;ILE A 333;GLN A 382","None","0.99A","3id5B-2qykA:undetectable","3id5B-2qykA:21.16"],["3ID5_F_SAMF301_0","FIBRILLARIN-LIKE RRNA\/TRNA 2'-O-METHYLTRANSFERASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"THR A 298;ASP A 379;ALA A 378;ILE A 333;GLN A 382","None","0.99A","3id5F-2qykA:undetectable","3id5F-2qykA:21.16"],["3JWQ_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;HIS A 372;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.90A","3jwqA-2qykA:39.2","3jwqA-2qykA:29.07"],["3JWQ_B_VIAB901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;HIS A 372;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.75A","3jwqB-2qykA:39.1;3jwqC-2qykA:39.2","3jwqB-2qykA:29.07;3jwqC-2qykA:29.07"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"TYR A 371;HIS A 372;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.81A","3jwqC-2qykA:39.2","3jwqC-2qykA:29.07"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",6,"TYR A 371;HIS A 372;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.6A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.84A","3jwqA-2qykA:39.2;3jwqD-2qykA:38.8","3jwqA-2qykA:29.07;3jwqD-2qykA:29.07"],["3R9V_B_DXCB1_0","INVASIN IPAD","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"ILE A 519;LEU A 522;LEU A 393;VAL A 504","None","0.88A","3r9vA-2qykA:undetectable;3r9vB-2qykA:undetectable","3r9vA-2qykA:21.02;3r9vB-2qykA:21.02"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",9,"TYR A 371;LEU A 531;ASN A 533;PRO A 534;THR A 545;ILE A 548;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);None;NPV A   3 (-4.4A);None;NPV A   3 ( 4.7A);NPV A   3 (-3.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.28A","3tvxA-2qykA:56.1","3tvxA-2qykA:98.82"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",7,"TYR A 371;ASN A 533;ILE A 548;PHE A 552;MET A 569;GLN A 581;PHE A 584","NPV A   3 (-4.4A);NPV A   3 (-4.4A);NPV A   3 (-3.8A);NPV A   3 (-4.8A);NPV A   3 (-3.1A);NPV A   3 (-3.1A);NPV A   3 (-3.3A)","0.24A","3tvxB-2qykA:56.1","3tvxB-2qykA:98.82"],["3WFH_B_P2EB301_1","MAB FAB H FRAGMENT;MAB FAB L FRAGMENT","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"HIS A 445;VAL A 448;HIS A 416;PRO A 417;LEU A 431","None","1.32A","3wfhA-2qykA:undetectable;3wfhB-2qykA:undetectable","3wfhA-2qykA:22.36;3wfhB-2qykA:20.53"],["3WHX_B_XPGB301_1","MAB FAB H FRAGMENT;MAB FAB L FRAGMENT","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"HIS A 445;VAL A 448;HIS A 416;PRO A 417;LEU A 431","None","1.31A","3whxA-2qykA:undetectable;3whxB-2qykA:undetectable","3whxA-2qykA:22.59;3whxB-2qykA:20.47"],["4AX8_A_SAMA1474_1","WBDD","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"TYR A 435;ASP A 415;GLU A 455;LEU A 446","None","1.21A","4ax8A-2qykA:undetectable","4ax8A-2qykA:22.22"],["4FP9_A_SAMA401_1","METHYLTRANSFERASE NSUN4","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"ASP A 616;ARG A 615;ASP A 609","None","0.85A","4fp9A-2qykA:undetectable","4fp9A-2qykA:23.81"],["4JBT_B_ASDB502_1","CYTOCHROME P450 MONOOXYGENASE","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"PHE A 338;ALA A 404;ALA A 405;THR A 384;VAL A 380","None","1.15A","4jbtB-2qykA:undetectable","4jbtB-2qykA:23.64"],["4RKU_A_PQNA5001_1","PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1;PHOTOSYSTEM I REACTION CENTER SUBUNIT IX","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"MET A 334;PHE A 338;ALA A 404;LEU A 403","None","0.99A","4rkuA-2qykA:undetectable;4rkuJ-2qykA:undetectable","4rkuA-2qykA:17.63;4rkuJ-2qykA:14.62"],["4XK8_A_PQNA844_1","PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"MET A 334;PHE A 338;ALA A 404;LEU A 403","None","1.01A","4xk8A-2qykA:undetectable","4xk8A-2qykA:17.69"],["4XK8_A_PQNA845_1","PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN A1","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"MET A 334;PHE A 338;ALA A 404;LEU A 403","None","1.00A","4xk8a-2qykA:undetectable","4xk8a-2qykA:17.69"],["4XO7_A_ASDA402_1","ALDO-KETO REDUCTASE FAMILY 1 MEMBER C2","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"VAL A 321;ILE A 318;LEU A 406;LEU A 381","None","0.81A","4xo7A-2qykA:undetectable","4xo7A-2qykA:23.34"],["5F8Y_A_X6XA202_1","GALNAC\/GAL-SPECIFIC LECTIN","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"GLU A 551;VAL A 369;HIS A 372;ASP A 413;HIS A 445","None;None;NPV A   3 (-4.6A); MG A   2 ( 2.6A);None","1.16A","5f8yA-2qykA:undetectable","5f8yA-2qykA:17.07"],["5F8Y_B_X6XB201_1","GALNAC\/GAL-SPECIFIC LECTIN","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",5,"GLU A 551;VAL A 369;HIS A 372;ASP A 413;HIS A 445","None;None;NPV A   3 (-4.6A); MG A   2 ( 2.6A);None","1.18A","5f8yB-2qykA:undetectable","5f8yB-2qykA:17.07"],["5V4V_A_NCAA402_0","NADPH DEHYDROGENASE 3","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"HIS A 527;PHE A 584;PRO A 534;TYR A 371","None;NPV A   3 (-3.3A);None;NPV A   3 (-4.4A)","1.28A","5v4vA-2qykA:undetectable","5v4vA-2qykA:21.29"],["5V4V_B_NCAB402_0","NADPH DEHYDROGENASE 3","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",4,"HIS A 527;PHE A 584;PRO A 534;TYR A 371","None;NPV A   3 (-3.3A);None;NPV A   3 (-4.4A)","1.29A","5v4vB-2qykA:undetectable","5v4vB-2qykA:21.29"],["5ZV2_B_LEVB801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","2qyk","CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE HSPDE4A10","Homo sapiens",3,"TYR A 371;LEU A 375;ASP A 323","NPV A   3 (-4.4A);None;None","0.87A","5zv2B-2qykA:undetectable","5zv2B-2qykA:12.84"]]